Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

White House Appeals To Shared Responsibility For Tackling Flu, Including H1N1, This Fall
White House officials said today that getting ready for the flu in the fall, whether it is seasonal flu or the ongoing H1N1 swine flu outbreak, is a
generic viagra online
Study Demonstrating Lurasidone Is Effective In Patients With Schizophrenia Published In The Journal Of Clinical Psychiatry
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical Psychiatry. This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy assessments at all study visits starting at day 3. In addition, lurasidone was generally well-tolerated and was associated with weight and metabolic changes that were similar to placebo.
News of the day
Employing People With Autism Could Save The UK Economy Billions Each Year
A unique event to discuss Autism and employment was held at Goldsmiths, University of London this week. For the first time charities, researchers, business and government were brought together to look at how people with Autism, and related disorders, can be supported effectively into employment.
Diagnostics

Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed"s first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed"s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients. Oramed"s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion. Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed"s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal." Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed"s technology is based on over 25 years of research by top research scientists at Jerusalem"s Hadassah Medical Center. The Company"s corporate and R&D headquarters are based in Jerusalem. Forward-looking statements Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company"s ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company"s filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. Oramed Pharmaceuticals Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009